StopAfib.org is pleased to unveil the Top Ten Atrial Fibrillation Articles of 2012. There were many topics of interest this year to the atrial fibrillation patient community. As always, the top interest was atrial fibrillation stroke prevention — that included the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for anticoagulants, the HAS-BLED tool …
Read MoreArchives
StopAfib interviews Dr. James Reiffel Find a transcript and more on Dr. Reiffel at: www.stopafib.org In this video interview at Heart Rhythm 2012, Dr. James Reiffel updates us on new directions in drug treatments for atrial fibrillation. He talks about the combination of ranolazine (Ranexa) and dronedarone (Multaq), both used …
Read MoreAt Heart Rhythm 2012, Dr. James Reiffel gave us an update on new medications for treating atrial fibrillation, including the combination of low doses of ranolazine (Ranexa) and dronedarone (Multaq). He also talked about rate control vs. rhythm control for afib, and how the decision can vary by age and level of symptoms. Watch the …
Read MoreIn follow up to our announcement yesterday of the Top Ten Atrial Fibrillation Videos of 2011, StopAfib.org now unveils the Top Ten Atrial Fibrillation Articles of 2011. Major topics of interest to the atrial fibrillation patient community this year were afib stroke prevention and the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for …
Read MoreAs a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them. There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits …
Read MoreIn this video from Boston Atrial Fibrillation Symposium 2010, Professor John Camm discusses the two newest antiarrhythmic drugs, dronedarone (Multaq®), which is now approved in the US and Europe for atrial fibrillation, and vernakalant, which is a year or two away. These antiarrhythmic (rhythm control) drugs help to put patients …
Read MoreAt Boston Atrial Fibrillation Symposium 2010, Prof. John Camm talked about the two newest antiarrhythmic drugs for atrial fibrillation treatment, dronedarone (Multaq®) and vernakalant. These antiarrhythmic (rhythm control) drugs help to put patients back into normal sinus rhythm, or to keep them in it. See the video: Interview with Professor John Camm at Boston Atrial …
Read MoreWe hear from so many afib patients every day about the trials, tribulations, and fears regarding being on amiodarone, or their refusal to take it. Since the FDA approved Multaq® (dronedarone) recently, the most frequent question I've fielded has been "When will Multaq® be available?" That happened this week, and the excitement they have shared …
Read MoreBREAKING NEWS Multaq(R), the much anticipated replacement for amiodarone, just received FDA approval. Read the press release: FDA Approves Multaq® for Patients with Atrial Fibrillation or Atrial Flutter
Read MoreFor those atrial fibrillation patients who are on amiodarone, or for those avoiding it, there is good news. Multaq® (dronedarone), a replacement for amiodarone, received priority review status from the US FDA. While amiodarone is among the most effective atrial fibrillation medications, it has major toxicity issues that dronedarone doesn't display. Read more...
Read More